Key statistics
On Friday, Arcutis Biotherapeutics Inc (ARQT:NSQ) closed at 10.15, -22.93% below its 52-week high of 13.17, set on Apr 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.17 |
---|---|
High | 10.31 |
Low | 9.78 |
Bid | 10.18 |
Offer | 10.29 |
Previous close | 10.14 |
Average volume | 2.14m |
---|---|
Shares outstanding | 116.89m |
Free float | 114.33m |
P/E (TTM) | -- |
Market cap | 1.19bn USD |
EPS (TTM) | -2.18 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
- Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
- Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
- CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
- Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
- Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
- Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
- Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
- FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
- Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
More ▼